This retrospective, cohort study showed subjects with raised ALT levels and uncontrolled T2DM initiated on SGLT2Is had a significant reduction of mean ALT levels and other study parameters over a period of 12 months. The gene discussed is GPT; the disease is type 2 diabetes mellitus.